Igyxos S.A. has completed a Series A fundraising
Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.
Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.
Oaklins’ team in France advised Igyxos on a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.
CSO and Founder, Igyxos, S.A.
Talk to the deal team
Senior AdvisorParis, France
Associate DirectorParis, France
TDK Corporation has divested its medical business HTI Medical to GTCR-backed Resonetics
Hutchinson Technology, Inc., a subsidiary of TDK Corporation, has sold its medical business HTI Medical to Resonetics, a portfolio company of GTCR.Learn more
Maginnis Orthodontics has been acquired by Smile Doctors
Maginnis Orthodontics, Inc. has been sold to Smile Doctors, LLC.Learn more
Pridiktiv has been acquired by Corilus
The shareholders and founders of Pridiktiv NV have sold the company to Corilus.Learn more